Join us to explore the latest insights into the future of precision oncology!
This year, the Agilent Precision Oncology Summit kicks off with webinars offering cutting-edge insights and practical guidance to enhance cancer care precision and advancing immunotherapy.
Stay ahead in your translational research and improve patient outcomes with precision medicine.
Speakers
Cancer Cell Gene Therapy
From Bench to Bedside: Translational Strategies in Advancing Immunotherapy for Solid Tumors – Insights from Liver Cancer Research
Dr. Timothy Shuen
Senior Research Fellow and Research Manager
National Cancer Centre Singapore
Singapore
Biography of Dr. Timothy Shuen:
Dr. Timothy Shuen is a Senior Research Fellow at the National Cancer Centre Singapore and the Research Manager of the Virus-Induced Cancers – Translational Oncology Research and Immunology (VICTORY) programme. He is a molecular cancer, immunology, and translational scientist with a strong interest in transgenic mouse modelling, multi-omics technologies such as single-cell and spatial transcriptomics, multiplexed immunofluorescence staining, single-cell T cell receptor (TCR) sequencing, and single-cell secretome/proteome analyses. His work focuses on their applications in scientific discovery, biomarker discovery, and advancing treatment strategies. Dr. Shuen obtained his PhD from the LKS Faculty of Medicine at the University of Hong Kong and has been awarded five scholarships and four scientific awards.
Next Generation Sequencing (NGS)
Methodology for Accurate Variant Calling from FFPE Using Agilent Panels
Dr. Seong-Eui Hong
Department Lead / Director, Big Data Division - Research & Development
Theragen Bio Co., Ltd
Korea
Biography of Dr. Seong-Eui Hong
Dr. Hong is the Department Lead / Director, Big Data Division - Research & Development at Theragen Bio in the Republic of Korea. She holds a Doctoral Degree in Bioinformatics from Pusan National University and a Master’s in Biotechnology from Handong University, where she also completed her Bachelor’s in Food and Biotechnology. Her professional experience includes roles as a Senior Consultant at Insilicogen, Research Fellow at Aju University and Gwangju Institute of Science and Technology, and Postdoctoral Researcher at the same institute. She has also worked as a Research Assistant at the Korea Research Institute of Bioscience and Biotechnology.
Harnessing Liquid Biopsy in Translational Cancer Research
Asst. Prof. Umberto Malapelle
Anatomic Pathology, Department of Public Health
University of Naples Federico II
Italy
Biography of Asst. Prof. Umberto Malapelle
Umberto Malapelle is an Assistant Professor in Anatomic Pathology at the University of Naples Federico II School of Medicine. He is currently the Chief Supervisor of the Predictive Molecular Pathology Laboratory in the Department of Public Health of the University Federico II of Naples and the scientific secretary of the International Society of Liquid Biopsy. His main research interest is in the field of genomic biomarkers validation and testing for predictive information in lung cancer, metastatic colorectal cancer, melanoma, and gastrointestinal stromal tumors. Moreover, he has developed skills in tailoring next-generation assays for a number of different applications with a special focus on simultaneously detecting clinically relevant alterations in the routine setting with different sample types, such as tissue and/or liquid biopsy specimens.
Prof. Paul Hofman
Pathologist
University Côte d’Azur, Nice
France
Biography of Prof. Paul Hofman
Paul Hofman is a Professor of Pathology at the University Côte d’Azur in Nice, France. He was a fellow in pathology at the Brigham and Women’s Hospital at Harvard Medical School and at the Max Planck Institut. He was awarded a Doctorate in Cell Biology at the University of Montpellier, in France. He is the head of the Laboratory of Clinical and Experimental Pathology at Louis Pasteur Hospital in Nice, the Director of the University Hospital Federation, FHU OncoAge, and of the Hospital-related Biobank, the Director of the MSc Biobanks and Complex Data Management at the University Côte d’Azur, Director of the Research Team 4 at Inserm aiming to determine the spectrum of genetic, non-genetic, and cellular events in lung cancer to better characterize the underlying mechanisms associated with non-response to therapy. His main research interest is in identifying biomarkers for non-response to immunotherapies and/or targeted therapies, and to improve therapeutic response with the next-generation combination of molecules. He is the Director of the Liquid Biopsy Center in Nice, which has been selected to be a European Expert Center in liquid biopsy. Since May 2023, he has been the new Director of the Institut Hospitalo-Universitaire RespirERA in Nice.
PD-L1
Evaluation of PD-L1 in Gastric Cancer
Dr Chen Xiu Fen
Pathologist, Associate Consultant
Singapore General Hospital
Singapore
Biography of Dr Chen Xiu Fen
Dr Chen Xiu Fen is an Associate Consultant in the Department of Anatomical Pathology at Singapore General Hospital, specialising in gastrointestinal, hepatobiliary, soft tissue, and bone pathology. Dr Chen completed a five-year Pathology training in SingHealth Residency programme, handling a diverse spectrum of challenging cases. Dr Chen was awarded the Fellowship of the Royal College of Pathologists of Australasia in 2022, and subsequently completed her pathology training in 2023. Dr Chen has also been involved in collaborative research, focusing on gastrointestinal and hepatobiliary pathology.
Current and Emerging Biomarkers in Gastric Cancer Management - A Pathologist’s Perspective
Dr Brendan Pang
Consultant Pathologist and Company Director
Avant-Garde Pathology Solutions
Singapore
Biography of Dr Brendan Pang
Dr Brendan Pang is the founding director of AGPS Pte Ltd and a Locum Histopathologist at Parkway Labs, as well as the Clinical Governance Officer of Angsana Molecular and Diagnostics Laboratory. His achievements include setting up turnkey NGS for Angsana Labs, and PD-L1 and HER2-DISH testing for Parkway Labs.
Understanding PD-L1 Assessment: Insights from Breast and Cervical Cancer Specimens
Dr. Philippe Taniere
Consultant Histopathologist/Molecular Pathologist
University Hospitals Birmingham NHS Foundation Trust
United Kingdom
Biography of Dr. Philippe Taniere
Dr Philippe Taniere graduated in Histopathology (MD) from the University of Lyon, France, in 1995. He obtained a PhD at the Unit of Molecular Carcinogenesis at the International Agency for Research on Cancer, Lyon in 2002.
Since October 2002, Dr Taniere is a Consultant in Histopathology at University Hospitals Birmingham (UHB) with an interest in Gastrointestinal tract Pathology, Lung tumours and Soft Tissue Sarcomas.
